Shares of Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $7.93, but opened at $7.34. Oxford BioMedica shares last traded at $7.34, with a volume of 100 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of “Hold”.
Get Our Latest Analysis on Oxford BioMedica
Oxford BioMedica Stock Performance
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Further Reading
- Five stocks we like better than Oxford BioMedica
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
